Skip to main content

ALC · Alcon Inc · Documents

Track ALC — free
$74.31 -0.19 (-0.26%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$35.70B
Shares
480.40M
Volume · Nov 20 3.42M Avg daily vol (3M) 1.99M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $10.4B up 4.9% 20-F filed Feb 24, 2026 Earnings call Q3 2026 earnings call Held Nov 11, 2026
2026
Nov 11
Earnings call
Sales outlook held while EPS growth guidance narrows

Alcon reported third-quarter sales of $2.7 billion, up 5%, and kept 2026 sales-growth guidance at approximately 6%. It narrowed core diluted EPS growth guidance to 12 to 14%; implantables sales fell 2% amid U.S. competitive pressure.

Read from the first part of this long document
5 source passages
Alcon's third quarter 2026 earnings conference call. our third quarter sales were $2.7 billion, up 5% versus prior year We expect sales growth of approximately 6%, consistent with the midpoint of our original guidance issued in February. narrowing our range on core diluted EPS growth to 12 to 14%. Turning to Implantable, sales were down 2%, with IOLs down 1%, driven primarily by competitive launches in the U.S. premium IOL category and continued reimbursement challenges for dual procedures and glaucoma implants. Open the document at this passage
Nov 10
Current report 6-K
Third-quarter sales rise 5%, core EPS up 15%

Alcon reported third-quarter 2026 sales of $2.7 billion, up 5%, and core diluted EPS of $0.91, up 15%. It tightened 2026 constant-currency sales growth guidance to +~6% and core diluted EPS growth guidance to +12% to +14%.

Read from the first part of this long document
4 source passages
Third-quarter 2026 sales of $2.7 billion, +5%, +5% constant currency1 (cc), vs. third-quarter 2025 Third quarter 2026 diluted EPS of $0.54, +13%, +14% cc; core diluted EPS2 of $0.91, +15%, +15% cc, vs. third-quarter 2025 Net sales growth vs. prior year (cc)1 (non-IFRS measure) | +5% to +7% | +~6% | Tightened Core diluted EPS2 growth vs. prior year (cc)1 (non-IFRS measure) | +12% to +15% | +12% to +14% | Tightened range Open the document at this passage
Feb 24
Annual report 20-F FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $10.4B ▲ 4.9% Net income $980M ▼ 3.7% Diluted EPS $1.98 ▼ 3.4%
2025
Feb 25
Annual report 20-F FY2024, ended Dec 31
Annual report for FY2024
Revenue $9.91B ▲ 4.8% Net income $1.02B ▲ 4.5% Diluted EPS $2.05 ▲ 4.6%
2024
Feb 27
Annual report 20-F FY2023, ended Dec 31
Annual report for FY2023
Revenue $9.46B ▲ 8.5% Net income $974M ▲ 190.7% Diluted EPS $1.96 ▲ 188.2%
2023
Feb 27
Annual report 20-F FY2022, ended Dec 31
Annual report for FY2022
Revenue $8.72B ▲ 5.1% Net income $335M ▼ 10.9% Diluted EPS $0.68 ▼ 10.5%
Showing 1–50 of 90 documents
Key facts CIK 1167379 CUSIP H01301128 13F (30d) 602 filings 526 filers Visit website Investor relations